Simoa單分子免疫陣列超靈敏細(xì)胞因子
檢測服務(wù)
產(chǎn)品介紹：
SimoaTM（Single Molecular Array）又稱作數(shù)字式ELISA，是基于Simoa HD-1數(shù)字式單分子免疫陣列分析儀，可直接對血清和血漿中蛋白、核酸等生物標(biāo)志物進(jìn)行檢測的技術(shù)。它的檢測靈敏度比傳統(tǒng)的免疫檢測技術(shù)平均高1000倍以上，將蛋白質(zhì)檢測技術(shù)直接帶入單分子、數(shù)字化檢測時代，成為fg級超低豐度蛋白質(zhì)檢測領(lǐng)域的優(yōu)勢技術(shù)。
技術(shù)原理：
1、將捕獲抗體偶聯(lián)到磁珠上，磁珠與目標(biāo)抗原結(jié)合，目的抗原與檢測抗體結(jié)合并帶有梅標(biāo)記。
2、洗滌磁珠以去除非特異性結(jié)合的蛋白，加入酶反應(yīng)底物。
3、將加入底物的磁珠轉(zhuǎn)入Simoa光盤上，將熒光信號封閉在小孔內(nèi)。
應(yīng)用領(lǐng)域：
Simoa技術(shù)可用于腫瘤、神經(jīng)、感染性疾病、免疫炎癥、miRNA檢測，特別是癌癥的早期檢測、術(shù)后的監(jiān)測和精準(zhǔn)用藥，將極大推動精準(zhǔn)醫(yī)療的發(fā)展。運(yùn)用Simoa可檢測到的低濃度生物標(biāo)志物進(jìn)行準(zhǔn)確分析，為生命科學(xué)研究、體外診斷、伴隨診斷和血液篩查等領(lǐng)域。目前在全球引用該技術(shù)發(fā)表的文獻(xiàn)有200多篇，包括高分雜志Nature, Nature Biotechnology, JEM, JAMA Neurology等。
參考文獻(xiàn)
[1] Gill J, Merchant-Borna K, Jeromin A, et al. Acute plasma tau relates to prolonged return to play after concussion[J]. Neurology, 2017, 88: 595-602.
[2] Lin YS, Lee WJ, Wang SJ, et al. Levels of plasma neuroflament light chain and cognitive function in patients with Alzheimer or Parkinson disease[J],2018, Science Report, 2018, 8: 018-35766.
[3] Sokoll LJ, Zhang Z, Chan DW, et al. Do Ultrasensitive Prostate Specifc Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?[J]. Journal of Urology, 2016, 195: 330-336.
[4] Byrne LM, Rodrigues FB, Blennow K, et al. Neuroflament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis[J]. Lancet Neurology, 2017, 16: 601-609.
[5] Mattsson N, Andreasson U, Zetterberg H,(2017) Association of Plasma Neuroflament Light With Neurodegeneration in Patients With Alzheimer Disease[J]. JAMA Neurology, 2017, 74: 557-566.
[6] Piehl F, Kockum I, Khademi M, et al. Plasma neuroflament light chain levels in patients with MS switching from injectable therapies to fngolimod[J]. Multiple Sclerosis Journal, 2018, 24: 1046-1054.
[7] Hansson O, Janelidze S, Hall S, et al. (2017) Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder[J]. Neurology, 2017, 88: 930-937.
[8] Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease[J]. Alzheimers Dement, 2018, 9: 33561-33561.
[9] Yanamandra K, Patel TK, Jiang H, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy[J]. Science Translation Medicine. 2017, 9 (386):eaal2029.
[10] Kawata K, Mitsuhashi M, Aldret R. A Preliminary Report on Brain-Derived Extracellular Vesicle as Novel Blood Biomarkers for Sport-Related Concussions[J]. Frontiers Neurology, 2018, 9:239.
